BioSpace News Archive

Biophytis SA released top-line results from its phase 2-3 COVA clinical study evaluating Sarconeos in the treatment of COVID-19-related respiratory failure.

Salipro Biotech AB announced that its patent entitled “Saposin lipoprotein particles and libraries from crude membranes” has been issued by both the U.S. Patent and Trademark Office and by the China National Intellectual Property Administration.

George Medicines announced that its novel single-pill, triple combination candidate, GMRx2, is being used in the VERONICA-Nigeria trial as a novel treatment for hypertension.

BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, announced topline results from an investigator-Sponsored Phase 2 clinical trial of NE3107 for the treatment of Alzheimer’s Disease.

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, honors National Muscular Dystrophy Awareness Month, an annual observance that raises awareness for families across the nation who are living with neuromuscular diseases.

Isofol Medical AB, reported data from the AGENT study that formed the basis for its assessment that it was not justified to continue the study.

Nuvalent, Inc. announced it will present preliminary dose escalation data from its ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive non-small cell lung cancer and other solid tumors during an oral plenary session at the 34th EORTC-NCI-AACR Symposium taking place October 26-28, 2022 in Barcelona, Spain.

Avivagen Inc. is pleased to announce that its scientific paper entitled “Safety and uptake of fully Oxidized Beta Carotene” has been published in the Journal of Food and Chemical Toxicology.

Pfizer Inc. announced that its investigational Group B Streptococcus vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy.

Velocity Clinical Research, the leading integrated research site organization, announces it has acquired MedPharmics, a multi-site company based in the US.